SNN - Osiris Therapeutics Is Undervalued In Buyout
Investment Thesis
While Osiris Therapeutics (OSIR) has appreciated 40% during the calendar year 2019, it is still significantly undervalued. The company's sales growth and earnings growth have been accelerating due to OSIR's increasing market success with its impactful suite of medical solutions that improve lives and hold down health care costs.
Business Summary
OSIR is a world leader in regenerative medicine that creates and delivers solutions for complex wound healing, orthopedics, sports medicine, and Acute Graft Versus Host Disease (aGVHD).
Osiris received marketing approval from Health Canada in 2012 for the world's first stem